📣 VC round data is live. Check it out!
- Public Comps
- NeuroPace
NeuroPace Valuation Multiples
Discover revenue and EBITDA valuation multiples for NeuroPace and similar public comparables like Sofwave Medical, Japan Lifeline, Tactile Medical, Bioventus and more.
NeuroPace Overview
About NeuroPace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Founded
1997
HQ

Employees
184
Website
Financials (LTM)
EV
$573M
Valuation Multiples
Start free trialNeuroPace Financials
NeuroPace reported last 12-month revenue of $100M and negative EBITDA of ($7M).
In the same LTM period, NeuroPace generated $81M in gross profit, ($7M) in EBITDA losses, and had net loss of ($20M).
Revenue (LTM)
NeuroPace P&L
In the most recent fiscal year, NeuroPace reported revenue of $100M and EBITDA of ($5M).
NeuroPace is unprofitable as of last fiscal year, with gross margin of 77%, EBITDA margin of (5%), and net margin of (21%).
Financial data powered by Morningstar, Inc.
NeuroPace Stock Performance
NeuroPace has current market cap of $556M, and enterprise value of $573M.
Market Cap Evolution
NeuroPace's stock price is $16.32.
NeuroPace share price decreased by 1.2% in the last 30 days, and increased by 47.6% in the last year.
NeuroPace has an EPS (earnings per share) of $-0.63.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $573M | $556M | -1.2% | -1.2% | 24.1% | 47.6% | $-0.63 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeuroPace Valuation Multiples
NeuroPace trades at 5.7x EV/Revenue multiple, and (86.6x) EV/EBITDA.
EV / Revenue (LTM)
NeuroPace Financial Valuation Multiples
As of June 3, 2026, NeuroPace has market cap of $556M and EV of $573M.
NeuroPace has a P/E ratio of (27.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NeuroPace Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


NeuroPace Margins & Growth Rates
NeuroPace decreased revenue by 0% but EBITDA grew by 76% in the last fiscal year.
In the most recent fiscal year, NeuroPace reported gross margin of 77%, EBITDA margin of (5%), and net margin of (21%).
NeuroPace Margins
NeuroPace Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
NeuroPace Operational KPIs
NeuroPace's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.5M for the same period.
NeuroPace's Rule of 40 is (9%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NeuroPace's Rule of X is (9%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
NeuroPace Competitors
NeuroPace competitors include Sofwave Medical, Japan Lifeline, Tactile Medical, Bioventus, Polynovo, Beta Bionics, Cytek Biosciences, Cerus, IBA Group and MiMedx Group.
Most NeuroPace public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 6.0x | - | 68.7x | - | |||
| 1.4x | 1.3x | 5.8x | 5.6x | |||
| 1.4x | 1.4x | 10.6x | 10.1x | |||
| 1.4x | 1.3x | 6.8x | 6.7x | |||
| 5.9x | 5.0x | 72.0x | 57.2x | |||
| 3.8x | 3.3x | (7.1x) | (5.9x) | |||
| 1.5x | 1.5x | (463.4x) | (186.0x) | |||
| 2.4x | 2.3x | 58.8x | 40.6x | |||
This data is available for Pro users. Sign up to see all NeuroPace competitors and their valuation data. Start Free Trial | ||||||
NeuroPace VC Funding History
Before going public, NeuroPace raised $159M in total equity funding, across 4 rounds.
NeuroPace Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NeuroPace
| When was NeuroPace founded? | NeuroPace was founded in 1997. |
| Where is NeuroPace headquartered? | NeuroPace is headquartered in United States. |
| How many employees does NeuroPace have? | As of today, NeuroPace has over 184 employees. |
| Who is the CEO of NeuroPace? | NeuroPace's CEO is Joel Becker. |
| Is NeuroPace publicly listed? | Yes, NeuroPace is a public company listed on Nasdaq. |
| What is the stock symbol of NeuroPace? | NeuroPace trades under NPCE ticker. |
| When did NeuroPace go public? | NeuroPace went public in 2021. |
| Who are competitors of NeuroPace? | NeuroPace main competitors include Sofwave Medical, Japan Lifeline, Tactile Medical, Bioventus, Polynovo, Beta Bionics, Cytek Biosciences, Cerus, IBA Group, MiMedx Group. |
| What is the current market cap of NeuroPace? | NeuroPace's current market cap is $556M. |
| What is the current revenue of NeuroPace? | NeuroPace's last 12 months revenue is $100M. |
| What is the current revenue growth of NeuroPace? | NeuroPace revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of NeuroPace? | Current revenue multiple of NeuroPace is 5.7x. |
| Is NeuroPace profitable? | No, NeuroPace is not profitable. |
| What is the current EBITDA of NeuroPace? | NeuroPace has negative EBITDA and is not profitable. |
| What is NeuroPace's EBITDA margin? | NeuroPace's last 12 months EBITDA margin is (7%). |
| What is the current EV/EBITDA multiple of NeuroPace? | Current EBITDA multiple of NeuroPace is (86.6x). |
| What is the current FCF of NeuroPace? | NeuroPace's last 12 months FCF is ($9M). |
| What is NeuroPace's FCF margin? | NeuroPace's last 12 months FCF margin is (9%). |
| What is the current EV/FCF multiple of NeuroPace? | Current FCF multiple of NeuroPace is (65.6x). |
| How many companies NeuroPace has acquired to date? | NeuroPace hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies NeuroPace has invested to date? | NeuroPace hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to NeuroPace
Lists including NeuroPace
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.